0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.

0.50 CME Credits. Dr. Collier explores diagnosis, overlapping symptoms, and treatments for delirium in older adults.

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.

0.50 CME Credits. Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.

Before you cook, oil the pan; before you plant that spring lawn, aerate the soil. Before you start a psych med, these are six things you need to have in place.

We interview psychoanalyst William Meyer on a therapeutic approach to postpartum depression.

We look at how often postpartum depression converts to bipolar, and what that means for treatment.

Today, we are focusing on how families are responding mentally and emotionally to disaster, and how children process loss when a parent or caregiver dies.

Brexanolone has quietly exited the pharmaceutical stage, and we look at what that means for its stand-in, zuranolone (Zurzuvae), in postpartum depression. 

You start a medication. The patient feels better in two weeks. You think: “Finally. This one works.” But six weeks later, the magic’s gone.

“When I’m manic, I feel like I put on Superman’s vest.” 

That’s how one patient explained why he didn’t want to stay on lithium. He wasn’t denying the crashes. He just wasn’t ready to give up the highs.
Another described it differently:
“If you take too much of it you're slightly underwater, but if you take too little you're floating three feet above the water.”

You’re sitting with a patient.

They’ve had terrible luck with sexual side effects.
And you’re silently trying to recall which SSRI is "less bad" on GI issues.
It’s not that you don’t know the data—it’s that it’s never all in one place.

How many times have you prescribed Abilify for depression and then stumbled over what to call it?

Do you say “antidepressant”?
“Mood stabilizer”?
Or do you tell the truth—“It’s an antipsychotic”—and watch your patient flinch?
We’ve all had this moment. The treatment fits. The label doesn’t.